Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pneumonia I: Introduction01:30

Pneumonia I: Introduction

1.3K
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
1.3K
Atypical Pneumonia01:14

Atypical Pneumonia

47
Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease...
47
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

1.2K
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
1.2K
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

4.2K
The pathophysiology of pneumonia involves the following steps:
4.2K
Pneumonia IV: Management01:28

Pneumonia IV: Management

1.1K
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
1.1K
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

4.0K
Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
4.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pulmonary Angiopathy in Severe COVID-19: Physiological Conclusions Derived from Ventilatory Ratio?

American journal of respiratory and critical care medicine·2020
Same author

Biomarkers in the ICU: less is more? No.

Intensive care medicine·2020
Same author

Updated guidance on the management of COVID-19: from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020).

European respiratory review : an official journal of the European Respiratory Society·2020
Same author

Reconsidering ventilator-associated pneumonia from a new dimension of the lung microbiome.

EBioMedicine·2020
Same author

Validation of a Prediction Score for Drug-Resistant Microorganisms in Community-acquired Pneumonia.

Annals of the American Thoracic Society·2020
Same author

Aetiological diagnosis in new adult outpatients with bronchiectasis:role of predictors derived from real life experience.

Respiratory medicine·2020
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
See all related articles

Related Experiment Video

Updated: Apr 5, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.8K

Community-acquired pneumonia.

Elena Prina1, Otavio T Ranzani2, Antoni Torres1

  • 1Department of Pulmonology, Hospital Clinic of Barcelona, University of Barcelona, Institut D'investigacions August Pi I Sunyer (IDIBAPS), Ciber de Enfermedades Respiratorias (CIBERES), Barcelona, Spain.

Lancet (London, England)
|August 17, 2015
PubMed
Summary
This summary is machine-generated.

Effective community-acquired pneumonia management requires individualized antibiotic therapy and close follow-up. This approach aims to reduce antibiotic resistance and improve patient outcomes, emphasizing timely oral shifts and clinical stability criteria.

More Related Videos

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice
15:43

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Published on: March 17, 2014

24.2K
Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling
08:25

Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling

Published on: April 7, 2015

9.6K

Related Experiment Videos

Last Updated: Apr 5, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.8K
Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice
15:43

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Published on: March 17, 2014

24.2K
Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling
08:25

Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling

Published on: April 7, 2015

9.6K

Area of Science:

  • Infectious Diseases
  • Pulmonology
  • Pharmacology

Background:

  • Community-acquired pneumonia (CAP) presents significant global mortality, morbidity, and economic burdens.
  • Empirical antibiotic selection is critical for managing CAP, but misuse contributes to resistance and adverse effects.

Purpose of the Study:

  • To outline principles for effective, individualized antibiotic treatment of CAP.
  • To highlight the importance of follow-up, early oral switch, and antibiotic stewardship.
  • To discuss novel diagnostic approaches and long-term implications of CAP.

Main Methods:

  • Review of current management strategies for community-acquired pneumonia.
  • Discussion of antibiotic stewardship principles and clinical stability criteria.
  • Exploration of emerging diagnostic technologies like lung ultrasound and molecular methods.

Main Results:

  • Optimized antibiotic use can mitigate resistance and side effects.
  • Early transition to oral antibiotics and tailored treatment duration are key.
  • Advanced diagnostics offer potential for faster and more accurate diagnosis.

Conclusions:

  • Individualized, evidence-based antibiotic strategies are essential for CAP management.
  • Close patient monitoring and stewardship are crucial for optimal outcomes.
  • Further research into long-term CAP sequelae and management is warranted.